Combination treatment of solifenacin plus tamsulosin for lower urinary tract symptoms in men with Parkinson′s disease

Abstract

Objective To investigate the efficacy and safety of a combination therapy of solifenacin plus tamsulosin for lower urinary tract symptoms (LUTS) in men with Parkinson′s disease. Methods From January 2010 to December 2013, 45 cases with LUTS symptoms associated with Parkinson′s disease were enrolled in this study. The average age was 62 years old (range 52-75 years old). The Parkinson′s disease history ranged from 1.0 to 10.5 years, mean 2.3 years. Before treatment, IPSS scores in those patients was 18.3±3.3. The maximum urinary flow rate (Qmax) was (8.5±3.9)ml/s. The OABSS scores were 10.9±2.2. The average postvoid residual (PVR) volume was (41.1±14) ml. The detrusor pressure at Qmax (PdetQmax) was (68.1±28.2) cmH2O. All patients accepted once-daily co-administration of tamsulosin 0.2 mg plus solifenacin 5 mg with the option of solifenacin increase to 10 mg at 4th week, underwent screening for 8 weeks. All patients accepted the ultrasonic urodynamic analysis before treatment and at the end of 8th weeks. IPSS scores, OABSS scores, Qmax, PVR and PdetQmax were evaluated. Besides these, the adverse reactions were recorded. Results IPSS scores were significantly improved at 4 weeks (13.3±2.4) and 8 weeks (12.6±2.2) (P 0.05), compared with that before treatment. And no significant decreasing of Qmax detrusor pressure (63.2±30.1 cmH2O) was noticed (P>0.05). The complication included dry mouth in 3 patients, blurred vision in 2 patients and constipation in 1 patient. No acute urinary retention was recorded. Conclusions Solifenacin Plus tamsulosin combination treatment may be optional treatment for lower urinary tract symptoms in men associated with Parkinson′s disease, which can obviously improve patients′ life quality without obvious adverse reactions. Key words: LUTS; Parkinson′s disease; Solifenacin; Tamsulosin